Biologis logo

HELSINKI, Finland, February, 2020. – Euformatics partners with bio.logis to enable laboratories using its tertiary analysis platform to provide patients with pharmacogenomic dosing recommendations.

While being the topic of countless talks at conferences about personalized medicine for more than a decade, there are encouraging signs, indicating that pharmacogenomic testing is finally finding its way into clinical care. This includes a growing number of national and international initiatives and implementation projects, a growing awareness and acceptance for PGx testing among the medical community as well as first milestones in terms of achieving coverage from health care systems in some countries. In the light of these developments Finland-based Euformatics and German company bio.logis GIM agreed a partnership in order to support diagnostic laboratories and hospitals already offering genetic diagnostic services, to add PGx testing to their menu.

Euformatics specializes in bioinformatics tools for genomic data quality management and variant interpretation aiming to help medical doctors and genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. Their variant interpretation platform omnomicsNGS is used by laboratories in Europe, the US and Asia-Pacific.

bio.logis offers its Genetic Information Management software solution for pharmacogenomics (GIMS.pharma) to hospitals and laboratories across Europe. GIMS translates genetic analysis data into validated information including the right treatment recommendations from the internationally renowned KNMP (the Royal Dutch Pharmacists Association). It also provides physicians and patients with clinical decision support via digital smart functions to make results easily applicable at the Point of Care.

Both companies want to enable laboratories to offer a significant added value to patients by combining both solutions. “It just makes sense. If labs are sequencing patients for diagnostic purposes, the genetic data is already there. Offering patients personalized dosing recommendations for hundreds of drugs on top will help to increase efficacy of drugs taken and reduce side effects.” explains Daniela Steinberger, CEO of bio.logis.

“We are excited to be able to offer this extra level of knowledge to labs through our partnership with bio.logis. For clinical labs which have an effect on real patient outcomes, information on personalised drug dosing based on patient genetic data could make a huge difference to their treatment plans” adds Christophe Roos, Euformatics CSO.

Both companies are confident that the demand for pharmacogenomic testing will continue to grow steadily over the coming years and that drug prescriptions based on patients’ genetic makeup will become a standard procedure in clinical routine.

About Euformatics

Euformatics is a Finnish software company that specialises in high standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. At present, our core solutions include omnomicsNGS; for clinical analysis and reporting of patient NGS data, and omnomicsQ; for NGS data quality management. For more information about us and our products, please visit

About bio.logis Genetic Information Management GmbH

bio.logis Genetic Information Management GmbH translates genetic data into medically leverageable information and makes it available to physicians and patients. To that end, it has developed a special “Genetic Information Management System (GIMS)” IT solution which, in the process chain required for genetic diagnostics, focuses on the “last mile” from physician to patient by merging raw genetic data with clinically leverageable knowledge for prompt application. GIMS supports physicians both in laboratories for automatically generating such expert content, and in hospitals with specific clinical suggestions. The physician reports and recommended action generated by GIMS is delivered straight to the point of care via laboratory and physician information systems as well as electronic health records. For more information about our company and our products, please visit

Press Relations:

Dr Maike Post

bio.logis Genetic Information Management GmbH

Altenhöferallee 3

D-60438 Frankfurt am Main

Phone: +49 (0) 69 3487391 31

Allyana Thomas

Euformatics Oy

Tekniikantie 12

FI-02150, Espoo

Phone: +358 (0) 40 0359846

Back to news listing